All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Liquid Biopsy Shows Potential for Detecting Sarcomatoid Features in RCC

August 23rd 2024

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

Weighing the Options: Considerations for Adjuvant CDK4/6 Inhibitor Selection in HR+ Breast Cancer

August 23rd 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

DSP-5336 Is Safe, Generates Responses in KMT2A+ or NPM1+ R/R AML

August 22nd 2024

Naval G. Daver, MD, discusses efficacy and safety data from the first-in-human phase 1/2 study investigating DSP-5336 for relapsed or refractory acute leukemia.

The HR-Positive Breast Cancer Treatment Paradigm Sits on the Cusp of Significant Shifts

August 22nd 2024

Shipra Gandhi, MD, highlights findings with oral SERDs in HR-positive breast cancer and options to consider after progression on CDK4/6 inhibitors.

Dr Jonathan Chernoff, Fox Chase Cancer Center Director, Named Fellow of Scientific Society

August 22nd 2024

Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, has been named a Fellow of the American Society for Cell Biology.

Enfortumab Vedotin Plus Pembrolizumab Approved in Canada for Advanced Bladder Cancer

August 22nd 2024

Enfortumab vedotin plus pembrolizumab has been approved by Health Canada for use in unresectable locally advanced or metastatic urothelial cancer.

Fulzerasib Approved in China for KRAS G12C–Mutant Advanced NSCLC

August 22nd 2024

China’s National Medical Products Administration has approved fulzerasib for the treatment of adult patients with advanced KRAS G12C–mutant NSCLC.

Olaparib Monotherapy Elicits Responses in HRR+ Prostate Cancer With High-Risk Biochemical Recurrence

August 22nd 2024

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.

From Bench to Bedside: HIF-2α Inhibition in RCC

August 22nd 2024

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

Case Study Highlights an Approach to Adjuvant Treatment in RCC

August 22nd 2024

Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.

ODAC Vote Aims to Introduce Clarity on Phase of Treatment Benefits in Resectable NSCLC

August 22nd 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail new trial design proposals for perioperative regimens in resectable NSCLC.

A New Wave of Endocrine Therapies Are Emerging in HR+ Breast Cancer

August 21st 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma

August 21st 2024

Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.

Navigating the Complexities of Cancer Care

August 21st 2024

The Allegheny Health Network's comprehensive cancer navigation program supports all cancer patients from diagnosis to treatment and beyond.

PRECISION 1 Trial to End After Nab-Sirolimus is Projected to Miss Efficacy Threshold in TSC1/2+ Solid Tumors

August 21st 2024

Aadi Bioscience will end the PRECISION 1 trial evaluating nab-sirolimus in solid tumors harboring TSC1/2 alterations.

FDA Accepts sBLA for First-Line Nivolumab Plus Ipilimumab in Unresectable HCC

August 21st 2024

The FDA has accepted a supplemental biologics license application for nivolumab plus ipilimumab for first-line unresectable hepatocellular carcinoma.

FDA Issues Complete Response Letter to Linvoseltamab BLA in R/R Multiple Myeloma

August 21st 2024

The FDA has issued a CRL to the BLA seeking approval of linvoseltamab for use in select patients with relapsed or refractory multiple myeloma.

Cancer Care in 2024: Striving to Overcome the Challenges

August 21st 2024

Manmeet S. Ahluwalia, MD, MBA, FASCO, discusses ongoing efforts to overcome challenges in cancer care in 2024.

Repotrectinib Adds to the Treatment Armamentarium for NTRK+ Advanced Solid Tumors

August 21st 2024

Luis E. Raez, MD, FACP, FCCP, FASCO, discusses the FDA approval of repotrectinib for NTRK-positive advanced solid tumors.

Targeted Cancer Vaccines Could Shift the Paradigm for HPV+ HNSCC

August 21st 2024

Katharine A. Price, MD, discusses the use of HPV-targeted immunotherapy vaccines in patients with HPV16-positive head and neck squamous cell carcinoma.